The association analysis between HLA-A*26 and Behçet’s disease

Abstract

The strongest genetic risk factor of Behçet’s disease (BD) is HLA-B*51. Our group previously reported that HLA-A*26 is independently associated with the risk of the onset of BD apart from HLA-B*51. Here, we re-evaluated the association between HLA-A*26 and BD in the Japanese population. We also performed a comprehensive literature search and meta-analyzed the extracted published data concerning the relationship between HLA-A*26 and BD to estimate the odds ratio (OR) of HLA-A*26 to BD. In this study, we genotyped 611 Japanese BD patients and 2,955 unrelated ethnically matched healthy controls. Genotyping results showed that the phenotype frequency of HLA-A*26 was higher in BD patients than in controls (OR = 2.12, 95% CI: 1.75–2.56). Furthermore, within the HLA-B*51-negative populations, the phenotype frequency of HLA-A*26 was significantly higher in BD patients than in controls (OR = 3.10, 95% CI: 2.43–3.95). Results obtained from meta-analysis combined with our data showed that the modified OR of HLA-A*26 became 1.80 (95% CI:1.58–2.06), whereas within the HLA-B*51-negative population, the modified OR became 4.02 (95% CI: 2.29–7.05). A subgroup analysis arranged by the geographical regions showed HLA-A*26 is in fact associated with the onset of BD in Northeast Asia (OR = 2.11, 95% CI: 1.75–2.56), but not in the Middle East or in Europe.

Contribution of HLA‐B*51:01 and ‐A*26:01 to Behçet's disease and their clinical association in Thai patients

“…This indicated that the HLA‐A*26:01 could be another susceptible allele for Thai BD patients who do not carry ‐B*51X, similar to that reported from Korea and Japan. Furthermore, although the presence of either HLA‐A*26:01 or ‐B*51:01 in this study was associated with any uveitis, posterior uveitis and significant visual impairment, the subclass analysis found no association between ‐A*26:01 and ocular involvement or visual impairment among ‐B*51X non‐carrier patients, as seen in the Korean and Japanese reports . However, the AF of HLA‐A*26:01 in this report was higher in BD patients with ocular involvement than those without, regardless of whether the former were HLA‐B*51:01 carriers or not, and although this allele did not reach statistical significance, it indicated possible association with ocular involvement in Thai BD patients.…”

“…and Japan, 5,19 but not in the Middle East or Europe. These alleles also were found to associate with ocular involvement and severity of visual impairment.…”

“…The association of HLA‐A*26 and ‐A*26:01 with BD has been reported from eastern and northeast Asian Countries such as Korea and Japan, but not in the Middle East or Europe. These alleles also were found to associate with ocular involvement and severity of visual impairment .…”

Successful prednisolone treatment of peripartum Behçet disease associated with HLA‐A26

“…While HLA-B51 is the strongest genetic risk factor of Behc ßet disease, HLA-A26 has also been recently associated. 1 HLA-A26 is especially frequent in Northeast Asia, including the Western Pacific Rim, such as Taiwan and Japan. 1 Prednisolone is one of the effective therapies used for the management of Behc ßet disease during pregnancy; however, the safety of corticosteroids during gestation is controversial.…”

“…1 HLA-A26 is especially frequent in Northeast Asia, including the Western Pacific Rim, such as Taiwan and Japan. 1 Prednisolone is one of the effective therapies used for the management of Behc ßet disease during pregnancy; however, the safety of corticosteroids during gestation is controversial. 2 A possible causal association between cleft lip, maternal complications and intrauterine growth retardation have been reported.…”